|
Increased fluid intake increases the urinary output, lowering the concentration of substances involved in stone formation. Hydration is recom-mended to reduce new stone formation. Paresthesia Paresthesia, an effect associated with the use of other carbonic anhydrase inhibitors, appears to be a common effect of TOPAMAX® . Adjustment of Dose in Renal Failure Text Continues Below
The major route of elimination of unchanged topiramate and its metabolites is via the kidney. Dosage adjustment may be required in patients with reduced renal function (see DOSAGE AND ADMINISTRATION).
Decreased Hepatic Function In hepatically impaired patients, topiramate should be administered with caution as the clearance of topiramate may be decreased. Information for Patients Patients taking TOPAMAX ® should be told to seek immediate medical attention if they experience blurred vision or periorbital pain. Patients, especially pediatric patients, treated with TOPAMAX ® should be monitored closely for evidence of decreased sweating and increased body temperature, especially in hot weather. Patients, particularly those with predisposing factors, should be instructed to maintain an adequate fluid intake in order to minimize the risk of renal stone formation [see PRECAUTIONS: General, for support regarding hydration as a preventative measure]. Patients should be warned about the potential for somnolence, dizziness, confusion, and difficulty concentrating and advised not to drive or operate machinery until they have gained sufficient experience on topiramate to gauge whether it adversely affects their mental and/ or motor performance. Additional food intake may be considered if the patient is losing weight while on this medication. Please refer to the end of the product labeling for important information on how to take TOPAMAX ® (topiramate capsules) Sprinkle Capsules. Laboratory Tests: Measurement of baseline and periodic serum bicarbonate during topiramate treatment is recommended (see WARNINGS). Page: << Prev | 1 | 2 | 3 | 4 | 5
|
.gif)
